학술논문
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes
Document Type
Letter
Author
Brunner, A.M.; Narayan, R.; Esteve, J.; Tovar, N.; Porkka, K.; Kontro, M.; Knapper, S.; Ottmann, O.G.; Traer, E.; Borate, U.M.; Scholl, S.; Garcia-Manero, G.; Vey, N.; Wermke, M.; Janssen, J.J.W.M.; Fleming, S.; Loo, S.; Naidu, P.; Sun, H.; Mohammed, A.; Han, M.; White, R.; Zhang, N.; Steensma, D.P.; Sabatos-Peyton, C.A.; Rinne, M.L.; Wei, A.H.
Source
In: American Journal of Hematology . (American Journal of Hematology, February 2024, 99(2):E32-E36)
Subject
Language
English
ISSN
10968652
03618609
03618609